This company listing is no longer active
Kinnate Biopharma (KNTE) Stock Overview
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KNTE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Kinnate Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.65 |
| 52 Week High | US$7.19 |
| 52 Week Low | US$1.04 |
| Beta | 1.34 |
| 1 Month Change | 2.32% |
| 3 Month Change | 6.43% |
| 1 Year Change | -56.84% |
| 3 Year Change | -90.86% |
| 5 Year Change | n/a |
| Change since IPO | -93.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNTE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | 2.3% | 0.8% |
| 1Y | -56.8% | 42.3% | 20.2% |
Return vs Industry: KNTE underperformed the US Biotechs industry which returned 7.6% over the past year.
Return vs Market: KNTE underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| KNTE volatility | |
|---|---|
| KNTE Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KNTE has not had significant price volatility in the past 3 months.
Volatility Over Time: KNTE's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 94 | Nima Farzan | www.kinnate.com |
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Kinnate Biopharma Inc. Fundamentals Summary
| KNTE fundamental statistics | |
|---|---|
| Market cap | US$125.15m |
| Earnings (TTM) | -US$112.65m |
| Revenue (TTM) | n/a |
Is KNTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNTE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$112.65m |
| Earnings | -US$112.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KNTE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/03 21:00 |
| End of Day Share Price | 2024/04/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kinnate Biopharma Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Choi | Goldman Sachs |
| Roger Song | Jefferies LLC |
| Christopher Raymond | Piper Sandler Companies |